Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T67054
(Former ID: TTDR00155)
|
|||||
| Target Name |
5-HT 1 receptor (5HT1R)
|
|||||
| Synonyms |
Serotonin receptor 1; 5-hydroxytryptamine receptor 1; 5-HT1 receptor
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Patented-recorded target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Anxiety disorder [ICD-11: 6B00-6B0Z] | |||||
| 2 | Depression [ICD-11: 6A70-6A7Z] | |||||
| 3 | Migraine [ICD-11: 8A80] | |||||
| BioChemical Class |
GPCR rhodopsin
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
| 1 | Befiperide | Drug Info | Terminated | Anxiety disorder | [2] | |
| 2 | FCE-25876 | Drug Info | Terminated | Major depressive disorder | [3] | |
| 3 | SRSS-023 | Drug Info | Terminated | Migraine | [4] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Agonist | [+] 5 Agonist drugs | + | ||||
| 1 | Aryl piperazine derivative 14 | Drug Info | [1] | |||
| 2 | Aryl piperazine derivative 15 | Drug Info | [1] | |||
| 3 | Aryl piperazine derivative 16 | Drug Info | [1] | |||
| 4 | RU 24969 | Drug Info | [7] | |||
| 5 | SRSS-023 | Drug Info | [8] | |||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | Befiperide | Drug Info | [5] | |||
| 2 | FCE-25876 | Drug Info | [6] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. | |||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000673) | |||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001389) | |||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019089) | |||||
| REF 5 | Behavioral Pharmacology of 5-ht. Paul Bevan, Paul Bevan Duphar, Alexander R. Cools. 2013. Figure(15.2). | |||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001389) | |||||
| REF 7 | Effect of chronic treatment with 5-HT1 agonist (8-OH-DPAT and RU 24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT1 and 5-HT2 agonists. Br J Pharmacol. 1986 Oct;89(2):377-84. | |||||
| REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019089) | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.